Company Overview
Profound Medical Corp. operates as a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapeutic systems for the image guided ablation of diseased tissue. The company's lead product TULSA-PRO system combines magnetic resonance imaging (MRI), robotically driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. It also provides Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. It operates in Canada, Germany, the United States, China, and Finland. Profound Medical Corp. is headquartered in Mississauga, Canada.
Why Investors Should Care
Revenue has grown at a 34.1% CAGR over the past five years.
Carries low leverage with a debt-to-equity ratio of 0.15.
Recent Developments
- Dec 2025 Revenue of $16.10M (+50.7% YoY); net profit $-42.57M.
- Trailing 12 Months Year-on-year growth — revenue +12.3%.
- 5-Year Trend Long-term compounding — revenue CAGR 34.1%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 34.06% |
| 1 Year: | 12.30% |
Stock Price Performance
| 1 Year: | +24.95% |
| 6 Months: | +30.21% |
| 3 Months: | +3.65% |
| 1 Month: | -8.10% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)45.86 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 34.1% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | PROF Profound Medical Corp. PHARMA | 6.81 | -6.88 | $248.79M | 0.00% | -57.78% | -73.53% | 34.06% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.22M | 1.95M | 2.54M | 2.62M | 2.21M | 5.29M | 5.98M | 5.34M | - |
| Cost of Revenue | - | - | - | 768.00K | 593.00K | 1.36M | 1.99M | 1.50M | - |
| Gross Profit | 866.00K | 1.42M | 1.79M | 1.85M | 1.62M | 3.93M | 3.99M | 3.83M | 1.95M |
| Operating Expenses | - | - | - | 13.02M | 15.42M | 12.84M | 11.36M | 11.85M | - |
| Operating Income | -7.88M | -7.84M | -9.00M | -11.17M | -13.81M | -8.91M | -7.37M | -8.02M | -11.07M |
| EBITDA | - | - | - | -11.00M | -13.66M | -8.77M | -7.26M | -7.92M | - |
| Interest Expense | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | -10.68M | -15.63M | -7.86M | -8.15M | -7.03M | - |
| Tax Provision | - | - | - | 41.00K | 64.00K | 121.00K | 26.00K | 25.00K | - |
| Net Income | -6.58M | -6.92M | -9.37M | -10.72M | -15.70M | -7.98M | -8.18M | -7.05M | -9.54M |
| Diluted EPS | 0.27 | 0.28 | 0.38 | -0.36 | -0.52 | -0.26 | -0.27 | -0.19 | -0.26 |
| R&D Expense | 3.94M | 4.21M | 4.17M | 4.81M | 6.10M | 5.42M | - | 5.26M | 5.65M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 6.68M | 7.20M | 10.68M | 16.10M |
| Cost of Revenue | - | 3.66M | 2.89M | 3.64M | 4.71M |
| Gross Profit | - | 3.02M | 4.31M | 7.04M | 11.39M |
| Operating Expenses | - | 32.62M | 32.96M | 40.10M | 52.65M |
| Operating Income | - | -29.60M | -28.65M | -33.06M | -41.25M |
| EBITDA | - | -26.60M | -27.72M | -32.13M | -40.69M |
| Interest Expense | 67.00K | 174.00K | 770.00K | - | - |
| Pretax Income | - | -28.38M | -28.45M | -27.82M | -42.32M |
| Tax Provision | - | 287.00K | -128.00K | -2.00K | 252.00K |
| Net Income | - | -28.67M | -28.32M | -27.82M | -42.57M |
| Diluted EPS | - | -1.38 | -1.34 | -1.12 | -1.41 |
| R&D Expense | - | - | 14.42M | 16.96M | 20.60M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 64.42M | 43.96M | 70.23M | 77.47M |
| Current Assets | - | 62.02M | 41.90M | 69.06M | 76.09M |
| Cash & Equivalents | - | 46.52M | 26.21M | 54.91M | 59.72M |
| Inventory | - | 7.94M | 6.99M | 5.80M | 8.24M |
| Receivables | - | 5.98M | 7.14M | 6.58M | 7.20M |
| Total Liabilities | - | 12.42M | 12.73M | 9.81M | 11.04M |
| Current Liabilities | - | 4.18M | 6.37M | 6.57M | 6.08M |
| Long Term Debt | - | 6.65M | 5.00M | 2.92M | 4.50M |
| Total Debt | - | 8.23M | 7.87M | 5.12M | 4.71M |
| Total Equity | - | 52.00M | 31.22M | 60.42M | 66.43M |
| Shares Outstanding | - | 20.88M | 21.37M | 30.04M | 36.29M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -25.80M | -22.61M | -23.45M | -38.21M |
| Investing Cash Flow | -593.00K | 0 | - | 0 | -242.00K |
| Financing Cash Flow | - | 7.03M | 1.76M | 54.70M | 41.14M |
| Capital Expenditure | -593.00K | - | - | - | -242.00K |
| Free Cash Flow | - | -25.80M | -22.61M | -23.45M | -38.45M |
| Net Change in Cash | - | -18.77M | -20.85M | 31.24M | 2.69M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | 45.2% | 59.9% | 65.9% | 70.8% |
| Operating Margin % | - | -443.1% | -398.0% | -309.6% | -256.3% |
| Net Margin % | - | -429.1% | -393.4% | -260.4% | -264.4% |
| ROE % | - | -55.1% | -90.7% | -46.0% | -64.1% |
| ROCE % | - | -49.1% | -76.2% | -51.9% | -57.8% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | FIL LTD | 6.49% | 2.37M | $13.89M |
| 2 | Gagnon Securities, LLC | 5.37% | 1.96M | $11.49M |
| 3 | Royce & Associates LP | 3.28% | 1.20M | $7.03M |
| 4 | Timelo Investment Management Inc. | 3.05% | 1.11M | $6.53M |
| 5 | Gagnon Advisors, LLC | 2.63% | 962.19K | $5.64M |
| 6 | Letko, Brosseau & Associates Inc. | 2.56% | 935.73K | $5.48M |
| 7 | Rosalind Advisors, Inc. | 2.27% | 828.12K | $4.85M |
| 8 | Z3 Capital Partners, LLC | 2.25% | 820.94K | $4.81M |
| 9 | MMCAP International, Inc. SPC | 1.84% | 671.36K | $3.93M |
| 10 | Ardsley Advisory Partners LP | 1.57% | 575.00K | $3.37M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for PROF
A medical device company will meet investors in New York. No webcast will be available. - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxQSzAxTkFWaUVLLWt6Q3ZyZHZhWkJzS01YYzZlZUhEdjNyeTZ4Mkp3UFNyQTlvNTd2a19WYW5UMnRUV3loREdBY3pHLWFxdWU2SS1HVUZpVGNqRXZqTGJMOVlhTFRDc05lVjYyNlNvSFYtdkJsa29rcWxZUi1QTUo1UzJqN0h1SHB3RUN1cn…
Profound Medical (PROF) Moves 8.2% Higher: Will This Strength Last? - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxOMlFhV3NXRWptNTFVc0dXcVNQYkswdG80eF9UU1I5VHdxZ3Ntc1VsS3AxSWJFc3hzMVdYS29LZ0V3djhTMGdHQWZMcDFuQnhyX1VtbUJRM1RoNm9rRHdna0pJOXBDMVRRTUpDOEF0OXhhX3V2Q05QQ25iV3N0ekFKT3ZkN3REOWVtZi1QOV…
(PROF) Movement as an Input in Quant Signal Sets - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMixgFBVV95cUxQNW9mREdzcTdEZEVHTmtvQ0cxaEIwRFlEbWFINnBHaG1pSTJZRUEySm5MTXoyTFRFdFBjWjNpNFc5T1hNeE5OMHVianJ4Uy10R056QTZvSnRldmltMUhIcnFsY1pFaU14WHlTN3kteFU5SF9QVFJTRlJOYWdiTE5QX2RXODRTRHp5d0EwVE…
3 AI Stock Winners & 3 Write-Offs – Prof. Damodaran - Meb Faber Research
<a href="https://news.google.com/rss/articles/CBMihgFBVV95cUxPRmFoTjQydndmX2RVRTB4Q2Vsam5DZ3pENnVkbnRweEN3YVZMSXBNZlBxMC1lOXRLYi1pN2w1eFJyWTQ4cWh3blBsc1VpN2Z6eHJrcVY4eG8yLTVWS0l5eWt3N2NaUHhBNFR5dE1nUzEtMS1Oc3lZMkQtTXAwUVlPcjQ1blREUQ?oc=5" t…
Mobileye stock plummets following Amnon Shashua’s departure - The Jerusalem Post
<a href="https://news.google.com/rss/articles/CBMihgFBVV95cUxPOU1haWFUZmt6MUdfUHlSRGhUVVVoNEdpVnFJRzViVXNEejZsb0ZWM3BxbTl4WnZ4TjZHUUdGR3FtS3k3S2ludWZjbHhWVFI5WGZoRHBRQUNlWG5MLXM0ZHNESVoyRGVlWFBnV2szNC1HQ3k4aFpqdEtKd1czS0hqeFJETDRlQQ?oc=5" t…
Rethinking the Rules of Retirement with Prof. James Choi - Yale School of Management
<a href="https://news.google.com/rss/articles/CBMigAFBVV95cUxNSnNHZlZmVE4tTERwUHJsTDkyVWVoekxvbnNXWEdSNXJiQlEzRlNWVmMzTDdLdXBHZGhPeE5TcnoyYk9sdXpTY19HYzVOdG05bXdVYUVjWGs3ZzdScy1lV0FyZHY4T3FFbURQTG9SVE12UEVwNlFRUGhadm9HakRoMg?oc=5" target="_…
PROF — Frequently Asked Questions
What is the current share price of Profound Medical Corp. (PROF)?
As of 2026-09-19 21:16 PDT, Profound Medical Corp. (PROF) trades at $6.81 on NasdaqCM. Its 52-week range is $3.87 to $8.65.
What is the market capitalisation of PROF?
Profound Medical Corp. (PROF) has a market capitalisation of $248.79M on NasdaqCM.
What is the P/E ratio of PROF?
PROF trades at a trailing price-to-earnings (P/E) ratio of -6.88. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 4.30.
What is the return on equity (ROE) of PROF?
PROF has a return on equity (ROE) of -73.53%. Its return on capital employed (ROCE) is -57.78%.
Is PROF a good stock to buy?
This page provides a data-driven analysis of Profound Medical Corp. (PROF), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.